|
|
|
|
|
|
|
|
|
|
British Journal of Cancer
Conclusion:
Decreased BRCA1
expression is associated with a 36-month survival improvement in
patients with EOC treated with IP chemotherapy. Although these results
merit validation in future studies, the results suggest that decreased
BRCA1 expression predicts for improved response to cisplatin-based IP
chemotherapy with cisplatin and paclitaxel.
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.